[go: up one dir, main page]

MX2017003219A - Derivados de tetrahidroquinolina como inihbidores de bromodominio. - Google Patents

Derivados de tetrahidroquinolina como inihbidores de bromodominio.

Info

Publication number
MX2017003219A
MX2017003219A MX2017003219A MX2017003219A MX2017003219A MX 2017003219 A MX2017003219 A MX 2017003219A MX 2017003219 A MX2017003219 A MX 2017003219A MX 2017003219 A MX2017003219 A MX 2017003219A MX 2017003219 A MX2017003219 A MX 2017003219A
Authority
MX
Mexico
Prior art keywords
bromodomain inhibitors
tetrahydroquinoline derivatives
tetrahydroquinoline
derivatives
bromodomain
Prior art date
Application number
MX2017003219A
Other languages
English (en)
Other versions
MX373845B (es
Inventor
John Atkinson Stephen
Jonathan Hirst David
Thomas Seal Jonathan
Roland Wellaway Christopher
G Humphreys Philip
J Lindon Matthew
g preston Alexander
Original Assignee
Glaxosmithkline Intellectual Property (No 2) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property (No 2) Ltd filed Critical Glaxosmithkline Intellectual Property (No 2) Ltd
Publication of MX2017003219A publication Critical patent/MX2017003219A/es
Publication of MX373845B publication Critical patent/MX373845B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos novedosos específicos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia como inhibidores de bromodominio.
MX2017003219A 2014-09-12 2015-09-09 Derivados de tetrahidroquinolina como inhibidores de bromodominio. MX373845B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049449P 2014-09-12 2014-09-12
PCT/EP2015/070665 WO2016038120A1 (en) 2014-09-12 2015-09-09 Tetrahydroquinoline derivatives as bromodomain inhibitors

Publications (2)

Publication Number Publication Date
MX2017003219A true MX2017003219A (es) 2017-06-19
MX373845B MX373845B (es) 2020-03-26

Family

ID=54065889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003219A MX373845B (es) 2014-09-12 2015-09-09 Derivados de tetrahidroquinolina como inhibidores de bromodominio.

Country Status (36)

Country Link
US (1) US10059699B2 (es)
EP (1) EP3191476B1 (es)
JP (1) JP6531167B2 (es)
KR (1) KR20170054421A (es)
CN (1) CN106687453B (es)
AR (1) AR101806A1 (es)
AU (1) AU2015314184B2 (es)
BR (1) BR112017004580A2 (es)
CA (1) CA2958159A1 (es)
CL (1) CL2017000587A1 (es)
CO (1) CO2017001601A2 (es)
CR (1) CR20170090A (es)
CY (1) CY1121369T1 (es)
DK (1) DK3191476T3 (es)
DO (1) DOP2017000058A (es)
EA (1) EA031679B9 (es)
ES (1) ES2705623T3 (es)
HR (1) HRP20182064T1 (es)
HU (1) HUE041694T2 (es)
IL (1) IL250397A0 (es)
LT (1) LT3191476T (es)
MA (1) MA40366A (es)
MX (1) MX373845B (es)
PE (1) PE20170675A1 (es)
PH (1) PH12017500348A1 (es)
PL (1) PL3191476T3 (es)
PT (1) PT3191476T (es)
RS (1) RS58135B1 (es)
SG (1) SG11201701043UA (es)
SI (1) SI3191476T1 (es)
SM (1) SMT201900019T1 (es)
TR (1) TR201820050T4 (es)
TW (1) TWI686389B (es)
UY (1) UY36292A (es)
WO (1) WO2016038120A1 (es)
ZA (1) ZA201700883B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2970283T3 (da) 2013-03-14 2021-01-25 Boehringer Ingelheim Int Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
EP3191487B1 (en) 2014-09-12 2019-08-07 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
WO2018111805A1 (en) * 2016-12-13 2018-06-21 St. Jude Children's Research Hospital Tetrahydroquinoline-based bromodomain inhibitors
AU2019372121A1 (en) 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
US11584756B2 (en) 2019-07-02 2023-02-21 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
EP4095128A1 (en) 2021-05-25 2022-11-30 Centre national de la recherche scientifique Tetrahydroquinoline (thq) coumpounds
CN116919963B (zh) * 2023-07-28 2025-09-12 浙江大学 一种基于水网络策略的溴结构域蛋白4活性化合物的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415764A4 (en) * 2009-03-31 2012-08-08 Kowa Co PROPHYLACTIC AND / OR THERAPEUTIC AGENT AGAINST ANEMIA WITH A TETRAHYDROCHINOLINE COMPOUND AS AN ACTIVE SUBSTANCE
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB201106743D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201106750D0 (en) 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201107325D0 (en) 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
SG11201506245QA (en) * 2013-03-14 2015-09-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors

Also Published As

Publication number Publication date
DK3191476T3 (en) 2019-01-14
JP2017526718A (ja) 2017-09-14
PH12017500348B1 (en) 2017-07-17
TR201820050T4 (tr) 2019-01-21
CO2017001601A2 (es) 2017-07-28
PT3191476T (pt) 2019-01-17
PL3191476T3 (pl) 2019-04-30
CL2017000587A1 (es) 2017-10-06
MA40366A (fr) 2017-07-19
WO2016038120A1 (en) 2016-03-17
HRP20182064T1 (hr) 2019-02-08
AU2015314184B2 (en) 2018-09-13
IL250397A0 (en) 2017-03-30
US20170298047A1 (en) 2017-10-19
UY36292A (es) 2016-04-29
TWI686389B (zh) 2020-03-01
CA2958159A1 (en) 2016-03-17
JP6531167B2 (ja) 2019-06-12
US10059699B2 (en) 2018-08-28
HUE041694T2 (hu) 2019-05-28
RS58135B1 (sr) 2019-02-28
TW201625587A (zh) 2016-07-16
PE20170675A1 (es) 2017-06-13
SMT201900019T1 (it) 2019-02-28
SG11201701043UA (en) 2017-03-30
EP3191476B1 (en) 2018-10-24
SI3191476T1 (sl) 2019-01-31
PH12017500348A1 (en) 2017-07-17
EP3191476A1 (en) 2017-07-19
ZA201700883B (en) 2021-08-25
DOP2017000058A (es) 2017-06-15
CR20170090A (es) 2017-05-08
KR20170054421A (ko) 2017-05-17
CN106687453A8 (zh) 2017-06-30
AR101806A1 (es) 2017-01-11
BR112017004580A2 (pt) 2018-01-23
LT3191476T (lt) 2019-01-10
CN106687453B (zh) 2019-07-19
CN106687453A (zh) 2017-05-17
EA031679B1 (ru) 2019-02-28
ES2705623T3 (es) 2019-03-26
CY1121369T1 (el) 2020-05-29
MX373845B (es) 2020-03-26
EA031679B9 (ru) 2019-04-30
AU2015314184A1 (en) 2017-03-09
EA201790484A1 (ru) 2017-10-31

Similar Documents

Publication Publication Date Title
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
MX2017001512A (es) Compuestos activos hacia bromodominios.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
GEP20217239B (en) Pharmaceutical composition
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112016012146A8 (pt) derivados de aminopiridina como inibidores de quinase da família tam
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
MX2015012416A (es) Compuestos heterociclicos y sus usos.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
GEP20217240B (en) Pharmaceutical composition
BR112016014880A2 (pt) Composição farmacêutica incluindo palonosetron
GT201600252A (es) Derivados de naftiridinadiona
IN2013MU03641A (es)
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
MX2015008588A (es) Composiciones y metodos para la transfeccion de polinucleótidos.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
MX2015016603A (es) Composiciones de corticosteroides.
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas

Legal Events

Date Code Title Description
FG Grant or registration